trial

This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia

NCTId NCT03859973
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 200 (actual)
Sponsored by Boehringer Ingelheim
Primary completion 2022-09-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
200 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2019-04-15
Primary completion
2022-09-30
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
BI 425809

Sponsors

Boehringer IngelheimLead Sponsor

Sites

50 total
Little Rock, United StatesRogers, United StatesEncino, United StatesGarden Grove, United StatesLemon Grove, United StatesMontclair, United StatesOakland, United StatesOrange, United StatesPico Rivera, United StatesSan Diego, United StatesTorrance, United StatesMaitland, United States

Linked catalysts

1
This Study Tests Whether BI 425809 Together With Brain Training Using a Computer — primary completion2022-09-30

Facts & assertions

4 sourced
Enrollment
200
Phase
PHASE2
Primary Completion Date
2022-09-30
Status
COMPLETED
relationships
The graph out of here
drug
BI 425809
drug
lead_sponsor
Boehringer Ingelheim
company
indication
Schizophrenia
indication
Schizophrenia
indication